I
Isamu Okamoto
Researcher at Kyushu University
Publications - 458
Citations - 25482
Isamu Okamoto is an academic researcher from Kyushu University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 64, co-authored 413 publications receiving 19982 citations. Previous affiliations of Isamu Okamoto include Emory University & Kumamoto University.
Papers
More filters
Journal ArticleDOI
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Masayuki Takeda,Isamu Okamoto,Yoshihiko Fujita,Tokuzo Arao,Hiroyuki Ito,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa +7 more
TL;DR: The results suggest that KRAS mutation is a negative predictor of response to EGFR-TKIs in EGFR mutation-positive patients with NSCLC.
Journal ArticleDOI
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
Kimio Yonesaka,Kenji Hirotani,Hisato Kawakami,Masayuki Takeda,Hiroyasu Kaneda,Kazuko Sakai,Isamu Okamoto,Kazuto Nishio,Pasi A. Jänne,Kazuhiko Nakagawa +9 more
TL;DR: Results indicate that patritumab can overcome heregulin-dependent EGFR inhibitor resistance in NSCLC in vitro and in vivo and suggest that it can be used in combination with EGFR TKIs to treat a subset of here gulin-overexpressing NSCLc patients.
Journal ArticleDOI
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Kentaro Tanaka,Kumiko Isse,Tomomichi Fujihira,Mitsuhiro Takenoyama,Laura Saunders,Sheila Bheddah,Yoichi Nakanishi,Isamu Okamoto +7 more
TL;DR: The results reveal that DLL3 is expressed in tumor specimens from most patients with SCLC, and they should inform the undertaking of clinical trials of Rova-T including an ongoing phase I study in Japan and global phase III trials.
Journal ArticleDOI
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
Wataru Okamoto,Isamu Okamoto,Tokuzo Arao,Kiyoko Kuwata,Erina Hatashita,Haruka Yamaguchi,Kazuko Sakai,Kazuyoshi Yanagihara,Kazuto Nishio,Kazuhiko Nakagawa +9 more
TL;DR: Crizotinib shows a marked antitumor action both in vitro and in vivo specifically in gastric cancer cells positive for MET amplification, suggesting that MET signaling is essential for the survival of MET amplification–positive cells.